Lestaurtinib: A multi-targeted FLT3 inhibitor

Amir T. Fathi, Mark J Levis

Research output: Contribution to journalArticle

Abstract

Internal tandem duplication mutations of FMS-like tyrosine kinase-3 (FLT3) have been associated with poor outcomes in acute myelogenous leukemia. Over the course of the last several years, multiple agents have been developed and studied as potential inhibitors of FLT3 with the hope of providing clinical benefit for these patients. Lestaurtinib, a multi-targeted indolocarbazole derivative that potently inhibits FLT3 autophosphorylation in vitro, has been the most extensively studied agent in clinical trials to date. Multiple late-phase trials are underway to study this agent in adult and pediatric leukemia. This article will summarize the historical development of the pharmacology of lestaurtinib, as well as the ongoing investigation of the agent in preclinical and clinical studies.

Original languageEnglish (US)
Pages (from-to)17-26
Number of pages10
JournalExpert Review of Hematology
Volume2
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Protein-Tyrosine Kinases
Acute Myeloid Leukemia
Leukemia
Clinical Trials
Pharmacology
Pediatrics
Mutation
lestaurtinib
In Vitro Techniques
Clinical Studies

Keywords

  • Acute myeloid leukemia
  • FLT3
  • Internal tandem duplication
  • Lestaurtinib
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology

Cite this

Lestaurtinib : A multi-targeted FLT3 inhibitor. / Fathi, Amir T.; Levis, Mark J.

In: Expert Review of Hematology, Vol. 2, No. 1, 2009, p. 17-26.

Research output: Contribution to journalArticle

@article{9d19b9a878964014b69a73a1e53528ab,
title = "Lestaurtinib: A multi-targeted FLT3 inhibitor",
abstract = "Internal tandem duplication mutations of FMS-like tyrosine kinase-3 (FLT3) have been associated with poor outcomes in acute myelogenous leukemia. Over the course of the last several years, multiple agents have been developed and studied as potential inhibitors of FLT3 with the hope of providing clinical benefit for these patients. Lestaurtinib, a multi-targeted indolocarbazole derivative that potently inhibits FLT3 autophosphorylation in vitro, has been the most extensively studied agent in clinical trials to date. Multiple late-phase trials are underway to study this agent in adult and pediatric leukemia. This article will summarize the historical development of the pharmacology of lestaurtinib, as well as the ongoing investigation of the agent in preclinical and clinical studies.",
keywords = "Acute myeloid leukemia, FLT3, Internal tandem duplication, Lestaurtinib, Tyrosine kinase inhibitor",
author = "Fathi, {Amir T.} and Levis, {Mark J}",
year = "2009",
doi = "10.1586/17474086.2.1.17",
language = "English (US)",
volume = "2",
pages = "17--26",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Lestaurtinib

T2 - A multi-targeted FLT3 inhibitor

AU - Fathi, Amir T.

AU - Levis, Mark J

PY - 2009

Y1 - 2009

N2 - Internal tandem duplication mutations of FMS-like tyrosine kinase-3 (FLT3) have been associated with poor outcomes in acute myelogenous leukemia. Over the course of the last several years, multiple agents have been developed and studied as potential inhibitors of FLT3 with the hope of providing clinical benefit for these patients. Lestaurtinib, a multi-targeted indolocarbazole derivative that potently inhibits FLT3 autophosphorylation in vitro, has been the most extensively studied agent in clinical trials to date. Multiple late-phase trials are underway to study this agent in adult and pediatric leukemia. This article will summarize the historical development of the pharmacology of lestaurtinib, as well as the ongoing investigation of the agent in preclinical and clinical studies.

AB - Internal tandem duplication mutations of FMS-like tyrosine kinase-3 (FLT3) have been associated with poor outcomes in acute myelogenous leukemia. Over the course of the last several years, multiple agents have been developed and studied as potential inhibitors of FLT3 with the hope of providing clinical benefit for these patients. Lestaurtinib, a multi-targeted indolocarbazole derivative that potently inhibits FLT3 autophosphorylation in vitro, has been the most extensively studied agent in clinical trials to date. Multiple late-phase trials are underway to study this agent in adult and pediatric leukemia. This article will summarize the historical development of the pharmacology of lestaurtinib, as well as the ongoing investigation of the agent in preclinical and clinical studies.

KW - Acute myeloid leukemia

KW - FLT3

KW - Internal tandem duplication

KW - Lestaurtinib

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=77952288527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952288527&partnerID=8YFLogxK

U2 - 10.1586/17474086.2.1.17

DO - 10.1586/17474086.2.1.17

M3 - Article

C2 - 21082990

AN - SCOPUS:77952288527

VL - 2

SP - 17

EP - 26

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 1

ER -